10 Best NASDAQ Stocks Under $50 to Buy

7. Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Upside potential as of June 16, 2025: 44.64%

On Monday, analysts at TD Cowen reaffirmed their Buy rating on Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), expressing confidence in the company’s mitapivat drug ahead of trial results.

The financial services firm believes that the drug will show considerable reductions in vaso-occlusive crises (VOCs) during the Phase 3 RISE-UP trial for sickle cell disease (SCD), with full results expected by the end of this year. With SCD’s sales potential of $4 billion, TD Cowen highlights the company’s position in this emerging market.

The company was also named TD Cowen’s top small to mid-cap pick as it views positive Phase 3 trial results to be the turnaround point for Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Having said that, the stock price could rise by as high as 100% by the year’s end. With the lead candidate FDA-approved and two more on the horizon, achieving the price target set by analysts doesn’t seem impossible.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) is a biopharmaceutical company incorporated in 2007. This Massachusetts-based company engages in the discovery and development of treatments in the area of cellular metabolism. With PYRUKYND (mitapivat) as its lead candidate, the giant aims to elevate and extend the lives of many.